Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration

Pharmacogenomics

Volumn 13, Issue 9, 2012, Pages 1037-1053

  Agosta, Elisa ^a   Lazzeri, Stefano ^a   Orlandi, Paola ^a   Figus, Michele ^a   Fioravanti, Anna ^a   Di Desidero, Teresa ^a   Sartini, Maria Sole ^a   Nardi, Marco ^a   Danesi, Romano ^a   Bocci, Guido ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

age related macular degeneration; angiogenesis; CFH; genetics; pharmacogenetics; VEGF A

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN A; VERTEPORFIN;

ALLELE; ANTIANGIOGENIC THERAPY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; GENETIC MARKER; GENOTYPE; HUMAN; PATHOGENESIS; PHARMACOGENETICS; PHOTODYNAMIC THERAPY; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SUBRETINAL NEOVASCULARIZATION; TREATMENT RESPONSE; VISUAL ACUITY; VISUAL IMPAIRMENT;

ANGIOGENESIS INHIBITORS; BLOOD VESSELS; COMPLEMENT FACTOR H; GENETIC ASSOCIATION STUDIES; HUMANS; INDIVIDUALIZED MEDICINE; NEOVASCULARIZATION, PATHOLOGIC; PHOTOCHEMOTHERAPY; POLYMORPHISM, SINGLE NUCLEOTIDE; PORPHYRINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84864396563     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.77     Document Type: Review

References (113)

1. Friedman DS, O'Colmain BJ, Munoz B et al. Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 122(4), 564-572 (2004).
2. Montezuma SR, Sobrin L, Seddon JM. Review of genetics in age related macular degeneration. Semin. Ophthalmol. 22(4), 229-240 (2007).
3. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N. Engl. J. Med. 358(24), 2606-2617 (2008).
4. de Jong PT. Age-related macular degeneration. N. Engl. J. Med. 355(14), 1474-1485 (2006).
5. Kvanta A, Algvere PV, Berglin L et al. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest. Ophthalmol. Vis. Sci. 37(9), 1929-1934 (1996).
6. Witmer AN, Vrensen GF, Van Noorden CJ et al. Vascular endothelial growth factors and angiogenesis in eye disease. Prog. Retin. Eye Res. 22(1), 1-29 (2003).
7. Frank RN. Growth factors in age-related macular degeneration:pathogenic and therapeutic implications. Ophthalmic Res. 29(5), 341-353 (1997).
8. Pasqualetti G, Danesi R, Del Tacca M et al. Vascular endothelial growth factor pharmacogenetics:a new perspective for anti-angiogenic therapy. Pharmacogenomics 8(1), 49-66 (2007).
9. Bhisitkul RB. Vascular endothelial growth factor biology:clinical implications for ocular treatments. Br. J. Ophthalmol. 90(12), 1542-1547 (2006).
10. Rakic JM, Lambert V, Devy L et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 44(7), 3186-3193 (2003).
11. Soker S, Takashima S, Miao HQ et al. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92(6), 735-745 (1998).
12. Keyt BA, Berleau LT, Nguyen HV et al. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J. Biol. Chem. 271(13), 7788-7795 (1996).
13. Konopatskaya O, Churchill AJ, Harper SJ et al. VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice. Mol. Vis. 12, 626-632 (2006).
14. Perrin RM, Konopatskaya O, Qiu Y et al. Diabetic retinopathy is associated with a switch in splicing from anti-to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia 48(11), 2422-2427 (2005).
15. Kliffen M, Sharma HS, Mooy CM et al. Increased expression of angiogenic growth factors in age-related maculopathy. Br. J. Ophthalmol. 81(2), 154-162 (1997).
16. Churchill AJ, Carter JG, Lovell HC et al. VEGF polymorphisms are associated with neovascular age-related macular degeneration. Hum. Mol. Genet. 15(19), 2955-2961 (2006).
17. Boekhoorn SS, Isaacs A, Uitterlinden AG et al. Polymorphisms in the vascular endothelial growth factor gene and risk of age-related macular degeneration:the Rotterdam Study. Ophthalmology 115(11), 1899-1903 (2008).
18. Janik-Papis K, Zaras M, Krzyzanowska A et al. Association between vascular endothelial growth factor gene polymorphisms and age-related macular degeneration in a Polish population. Exp. Mol. Pathol. 87(3), 234-238 (2009).
19. Lin JM, Wan L, Tsai YY et al. Vascular endothelial growth factor gene polymorphisms in age-related macular degeneration. Am. J. Ophthalmol. 145(6), 1045-1051 (2008).
20. Shalaby F, Rossant J, Yamaguchi TP et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376(6535), 62-66 (1995).
21. Fang AM, Lee AY, Kulkarni M et al. Polymorphisms in the VEGFA and VEGFR-2 genes and neovascular age-related macular degeneration. Mol. Vis. 15, 2710-2719 (2009).
22. Galan A, Ferlin A, Caretti L et al. Association of age-related macular degeneration with polymorphisms in vascular endothelial growth factor and its receptor. Ophthalmology 117(9), 1769-1774 (2010).
23. Klein RJ, Zeiss C, Chew EY et al. Complement factor H polymorphism in age-related macular degeneration. Science 308(5720), 385-389 (2005).
24. Edwards AO, Ritter R 3rd, Abel KJ et al. Complement factor H polymorphism and age-related macular degeneration. Science 308(5720), 421-424 (2005).
25. Hageman GS, Anderson DH, Johnson LV et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc. Natl Acad. Sci. USA 102(20), 7227-7232 (2005).
26. Haines JL, Hauser MA, Schmidt S et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 308(5720), 419-421 (2005).
27. Johnson LV, Leitner WP, Staples MK et al. Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. Exp. Eye Res. 73(6), 887-896 (2001).
28. Scholl HP, Charbel Issa P, Walier M et al. Systemic complement activation in age-related macular degeneration. PLoS ONE 3(7), E2593 (2008).
29. Sivaprasad S, Chong NV. The complement system and age-related macular degeneration. Eye (Lond.) 20(8), 867-872 (2006).
30. Majewski J, Schultz DW, Weleber RG et al. Age-related macular degeneration-a genome scan in extended families. Am. J. Hum. Genet. 73(3), 540-550 (2003).
31. Seddon JM, Santangelo SL, Book K et al. A genomewide scan for age-related macular degeneration provides evidence for linkage to several chromosomal regions. Am. J. Hum. Genet. 73(4), 780-790 (2003).
32. Iyengar SK, Song D, Klein BE et al. Dissection of genomewide-scan data in extended families reveals a major locus and oligogenic susceptibility for age-related macular degeneration. Am. J. Hum. Genet. 74(1), 20-39 (2004).
33. Kenealy SJ, Schmidt S, Agarwal A et al. Linkage analysis for age-related macular degeneration supports a gene on chromosome 10q26. Mol. Vis. 10, 57-61 (2004).
34. Weeks DE, Conley YP, Tsai HJ et al. Age-related maculopathy:a genomewide scan with continued evidence of susceptibility loci within the 1q31, 10q26, and 17q25 regions. Am. J. Hum. Genet. 75(2), 174-189 (2004).
35. Seddon JM, Gensler G, Rosner B. C-reactive protein and CFH, ARMS2/HTRA1 gene variants are independently associated with risk of macular degeneration. Ophthalmology 117(8), 1560-1566 (2010).
36. Rivera A, Fisher SA, Fritsche LG et al. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk. Hum. Mol. Genet. 14(21), 3227-3236 (2005).
37. Fritsche LG, Loenhardt T, Janssen A et al. Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA. Nat. Genet. 40(7), 892-896 (2008).
38. Kanda A, Chen W, Othman M et al. A variant of mitochondrial protein LOC387715/ARMS2, not HTRA1, is strongly associated with age-related macular degeneration. Proc. Natl Acad. Sci. USA 104(41), 16227-16232 (2007).
39. Wang G, Spencer KL, Court BL et al. Localization of age-related macular degeneration-associated ARMS2 in cytosol, not mitochondria. Invest. Ophthalmol. Vis. Sci. 50(7), 3084-3090 (2009).
40. Kortvely E, Hauck SM, Duetsch G et al. ARMS2 is a constituent of the extracellular matrix providing a link between familial and sporadic age-related macular degenerations. Invest. Ophthalmol. Vis. Sci. 51(1), 79-88 (2010).
41. Tong Y, Liao J, Zhang Y et al. LOC387715/HTRA1 gene polymorphisms and susceptibility to age-related macular degeneration:a HuGE review and meta-analysis. Mol. Vis. 16, 1958-1981 (2010).
42. Tocharus J, Tsuchiya A, Kajikawa M et al. Developmentally regulated expression of mouse HtrA3 and its role as an inhibitor of TGF-b signaling. Dev. Growth Differ. 46(3), 257-274 (2004).
43. Miyake K, Horikawa Y, Hara K et al. Association of TCF7L2 polymorphisms with susceptibility to Type 2 diabetes in 4,087 Japanese subjects. J. Hum. Genet. 53(2), 174-180 (2008).
44. Ly DH, Lockhart DJ, Lerner RA et al. Mitotic misregulation and human aging. Science 287(5462), 2486-2492 (2000).
45. Grau S, Richards PJ, Kerr B et al. The role of human HtrA1 in arthritic disease. J. Biol. Chem. 281(10), 6124-6129 (2006).
46. Oka C, Tsujimoto R, Kajikawa M et al. HtrA1 serine protease inhibits signaling mediated by Tgfb family proteins. Development 131(5), 1041-1053 (2004).
47. Dewan A, Liu M, Hartman S et al. HTRA1 promoter polymorphism in wet age-related macular degeneration. Science 314(5801), 989-992 (2006).
48. Yang Z, Camp NJ, Sun H et al. A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science 314(5801), 992-993 (2006).
49. Francis PJ, Appukuttan B, Simmons E et al. Rhesus monkeys and humans share common susceptibility genes for age-related macular disease. Hum. Mol. Genet. 17(17), 2673-2680 (2008).
50. Kaur I, Katta S, Hussain A et al. Variants in the 10q26 gene cluster (LOC387715 and HTRA1) exhibit enhanced risk of age-related macular degeneration along with CFH in Indian patients. Invest. Ophthalmol. Vis. Sci. 49(5), 1771-1776 (2008).
51. Deangelis MM, Ji F, Adams S et al. Alleles in the HtrA serine peptidase 1 gene alter the risk of neovascular age-related macular degeneration. Ophthalmology 115(7), 1209-1215.E7 (2008).
52. Hughes AE, Orr N, Patterson C et al. Neovascular age-related macular degeneration risk based on CFH, LOC387715/HTRA1, and smoking. PLoS Med. 4(12), E355 (2007).
53. Lu F, Hu J, Zhao P et al. HTRA1 variant increases risk to neovascular age-related macular degeneration in Chinese population. Vision Res. 47(24), 3120-3123 (2007).
54. Yoshida T, DeWan A, Zhang H et al. HTRA1 promoter polymorphism predisposes Japanese to age-related macular degeneration. Mol. Vis. 13, 545-548 (2007).
55. Mahley RW. Apolipoprotein E:cholesterol transport protein with expanding role in cell biology. Science 240(4852), 622-630 (1988).
56. Anderson DH, Mullins RF, Hageman GS et al. A role for local inflammation in the formation of drusen in the aging eye. Am. J. Ophthalmol. 134(3), 411-431 (2002).
57. Dithmar S, Sharara NA, Curcio CA et al. Murine high-fat diet and laser photochemical model of basal deposits in Bruch membrane. Arch. Ophthalmol. 119(11), 1643-1649 (2001).
58. Ong JM, Zorapapel NC, Rich KA et al. Effects of cholesterol and apolipoprotein E on retinal abnormalities in ApoE-deficient mice. Invest. Ophthalmol. Vis. Sci. 42(8), 1891-1900 (2001).
59. Simonelli F, Margaglione M, Testa F et al. Apolipoprotein E polymorphisms in age-related macular degeneration in an Italian population. Ophthalmic Res. 33(6), 325-328 (2001).
60. Schmidt S, Klaver C, Saunders A et al. A pooled case-control study of the apolipoprotein E (APOE) gene in age-related maculopathy. Ophthalmic Genet. 23(4), 209-223 (2002).
61. Zareparsi S, Reddick AC, Branham KE et al. Association of apolipoprotein E alleles with susceptibility to age-related macular degeneration in a large cohort from a single center. Invest. Ophthalmol. Vis. Sci. 45(5), 1306-1310 (2004).
62. McKay GJ, Patterson CC, Chakravarthy U et al. Evidence of association of APOE with age-related macular degeneration:a pooled analysis of 15 studies. Hum. Mutat. 32(12), 1407-1416 (2011).
63. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration:two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in photodynamic therapy report 2. Am. J. Ophthalmol. 131(5), 541-560 (2001).
64. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin:one-year results of 2 randomized clinical trials-TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch. Ophthalmol. 117(10), 1329-1345 (1999).
65. Prasad PS, Schwartz SD, Hubschman JP. Age-related macular degeneration:current and novel therapies. Maturitas 66(1), 46-50 (2010).
66. Salam A, Mathew R, Sivaprasad S. Treatment of proliferative diabetic retinopathy with anti-VEGF agents. Acta Ophthalmol. 89(5), 405-411 (2011).
67. Waheed NK, Miller JW. Aptamers, intramers, and vascular endothelial growth factor. Int. Ophthalmol. Clin. 44(3), 11-22 (2004).
68. Gragoudas ES, Adamis AP, Cunningham ET Jr et al. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. 351(27), 2805-2816 (2004).
69. D'Amico DJ, Masonson HN, Patel M et al. Pegaptanib sodium for neovascular age-related macular degeneration:two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 113(6), 992-1001.E6 (2006).
70. Avery RL, Pieramici DJ, Rabena MD et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113(3), 363-372.E5 (2006).
71. Spaide RF, Laud K, Fine HF et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 26(4), 383-390 (2006).
72. Arevalo JF, Fromow-Guerra J, Sanchez JG et al. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration:results of the Pan-American collaborative retina study group at 12 months follow-up. Retina 28(10), 1387-1394 (2008).
73. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin):results of the Pan-American collaborative retina study group (PACORES). Graefes. Arch. Clin. Exp. Ophthalmol. 246(1), 81-87 (2008).
74. Patel PJ, Bunce C, Tufail A. A randomised, double-masked Phase III/IV study of the efficacy and safety of Avastin(R) (Bevacizumab) intravitreal injections compared with standard therapy in subjects with choroidal neovascularisation secondary to age-related macular degeneration:clinical trial design. Trials 9, 56 (2008).
75. Tufail A, Patel PJ, Egan C et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial):multicentre randomised double masked study. BMJ 340, C2459 (2010).
76. Martin DF, Maguire MG, Ying GS et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 364(20), 1897-1908 (2011).
77. Polak MB, Behar-Cohen F. Exudative age-related macular degeneration:efficacy and limits of the different treatments. J. Fr. Ophtalmol. 31(5), 537-556 (2008).
78. Mordenti J, Cuthbertson RA, Ferrara N et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol. Pathol. 27(5), 536-544 (1999).
79. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9(6), 669-676 (2003).
80. Rosenfeld PJ, Schwartz SD, Blumenkranz MS et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 112(6), 1048-1053 (2005).
81. Steinbrook R. The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration. N. Engl. J. Med. 355(14), 1409-1412 (2006).
82. Folk JC, Stone EM. Ranibizumab therapy for neovascular age-related macular degeneration. N. Engl. J. Med. 363(17), 1648-1655 (2010).
83. Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355(14), 1419-1431 (2006).
84. Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 355(14), 1432-1444 (2006).
85. Brown DM, Michels M, Kaiser PK et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration:two-year results of the ANCHOR study. Ophthalmology 116(1), 57-65.E5 (2009).
86. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration:PIER study year 2. Am. J. Ophthalmol. 150(3), 315-324.E1 (2010).
87. Schmidt-Erfurth U, Eldem B, Guymer R et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration:the EXCITE study. Ophthalmology 118(5), 831-839 (2011).
88. Lalwani GA, Rosenfeld PJ, Fung AE et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration:year 2 of the PrONTO study. Am. J. Ophthalmol. 148(1), 43-58.E1 (2009).
89. Holz FG, Amoaku W, Donate J et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration:the SUSTAIN study. Ophthalmology 118(4), 663-671 (2011).
90. Curtis LH, Hammill BG, Qualls LG et al. Treatment patterns for neovascular age-related macular degeneration:analysis of 284 380 medicare beneficiaries. Am. J. Ophthalmol. 153(6), 1116-1124.e1 (2012).
91. Wolf CR, Smith G, Smith RL. Science, medicine, and the future:pharmacogenetics. BMJ 320(7240), 987-990 (2000).
92. Parmeggiani F, Gemmati D, Costagliola C et al. Predictive role of gene polymorphisms affecting thrombin-generation pathway in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration. Recent Pat. DNA Gene Seq. 3(2), 114-122 (2009).
93. Parmeggiani F, Costagliola C, Gemmati D et al. Predictive role of coagulation-balance gene polymorphisms in the efficacy of photodynamic therapy with verteporfin for classic choroidal neovascularization secondary to age-related macular degeneration. Pharmacogenet. Genomics 17(12), 1039-1046 (2007).
94. Parmeggiani F, Gemmati D, Costagliola C et al. Predictive role of C677T MTHFR polymorphism in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration. Pharmacogenomics 10(1), 81-95 (2009).
95. Parmeggiani F, Costagliola C, Gemmati D et al. Coagulation gene predictors of photodynamic therapy for occult choroidal neovascularization in age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 49(7), 3100-3106 (2008).
96. Chowers I, Meir T, Lederman M et al. Sequence variants in HTRA1 and LOC387715/ARMS2 and phenotype and response to photodynamic therapy in neovascular age-related macular degeneration in populations from Israel. Mol. Vis. 14, 2263-2271 (2008).
97. Chowers I, Cohen Y, Goldenberg-Cohen N et al. Association of complement factor H Y402H polymorphism with phenotype of neovascular age related macular degeneration in Israel. Mol. Vis. 14, 1829-1834 (2008).
98. Goverdhan SV, Hannan S, Newsom RB et al. An analysis of the CFH Y402H genotype in AMD patients and controls from the UK, and response to PDT treatment. Eye (Lond.) 22(6), 849-854 (2008).
99. Seitsonen SP, Jarvela IE, Meri S et al. The effect of complement factor H Y402H polymorphism on the outcome of photodynamic therapy in age-related macular degeneration. Eur. J. Ophthalmol. 17(6), 943-949 (2007).
100. Brantley MA Jr, Edelstein SL, King JM et al. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy. Eye (Lond.) 23(3), 626-631 (2009).
101. Feng X, Xiao J, Longville B et al. Complement factor H Y402H and C-reactive protein polymorphism and photodynamic therapy response in age-related macular degeneration. Ophthalmology 116(10), 1908-1912.E1 (2009).
102. Tsuchihashi T, Mori K, Horie-Inoue K et al. Complement factor H and high-temperature requirement A-1 genotypes and treatment response of age-related macular degeneration. Ophthalmology 118(1), 93-100 (2011).
103. Immonen I, Seitsonen S, Tommila P et al. Vascular endothelial growth factor gene variation and the response to photodynamic therapy in age-related macular degeneration. Ophthalmology 117(1), 103-108 (2010).
104. Brantley MA Jr, Fang AM, King JM et al. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 114(12), 2168-2173 (2007).
105. Nischler C, Oberkofler H, Ortner C et al. Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration. Acta Ophthalmol. 89(4), E344-E349 (2010).
106. Nakata I, Yamashiro K, Nakanishi H et al. VEGF gene polymorphism and response to intravitreal bevacizumab and triple therapy in age-related macular degeneration. Jpn J. Ophthalmol. 55(5), 435-443 (2011).
107. Imai D, Mori K, Horie-Inoue K et al. CFH, VEGF, and PEDF genotypes and the response to intravitreous injection of bevacizumab for the treatment of age-related macular degeneration. J. Ocul. Biol. Dis. Infor. 3(2), 53-59 (2010).
108. Lee AY, Raya AK, Kymes SM et al. Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. Br. J. Ophthalmol. 93(5), 610-613 (2009).
109. Teper SJ, Nowinska A, Pilat J et al. Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration. Mol. Vis. 16, 2598-2604 (2010).
110. Kloeckener-Gruissem B, Barthelmes D, Labs S et al. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. Invest. Ophthalmol. Vis. Sci. 52(7), 4694-4702 (2011).
111. Wickremasinghe SS, Xie J, Lim J et al. Variants in the APOE gene are associated with improved outcome after anti-VEGF treatment for neovascular AMD. Invest. Ophthalmol. Vis. Sci. 52(7), 4072-4079 (2011).
112. McKibbin M, Ali M, Bansal S et al. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration. Br. J. Ophthalmol. 96(2), 208-212 (2012).
113. Bocci G, Loupakis F. Bevacizumab pharmacogenetics in tumor treatment:still looking for the right pieces of the puzzle. Pharmacogenomics 12(8), 1077-1080 (2011).